Literature DB >> 17713826

Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

Andrew Chan, De-Hyung Lee, Ralf Linker, Alexander Mohr, Klaus V Toyka, Ralf Gold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17713826     DOI： 10.1007/s00415-007-0593-9

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

Review 1.  B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.

Authors:  Edgar Meinl; Markus Krumbholz; Reinhard Hohlfeld
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

2.  Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.

Authors:  Nancy L Monson; Petra D Cravens; Elliot M Frohman; Kathleen Hawker; Michael K Racke
Journal:  Arch Neurol       Date:  2005-02

3.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Authors:  Mark Keegan; Fatima König; Robyn McClelland; Wolfgang Brück; Yazmín Morales; Andreas Bitsch; Hillel Panitch; Hans Lassmann; Brian Weinshenker; Moses Rodriguez; Joseph Parisi; Claudia F Lucchinetti
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

4.  Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Authors:  Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Journal:  Arch Neurol       Date:  2005-10

5.  Myasthenia gravis: remission not induced by blocking anti-idiotype antibodies.

Authors:  K Heininger; M Hendricks; K V Toyka; H Kolb
Journal:  Muscle Nerve       Date:  1983-06       Impact factor: 3.217

6.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

7.  Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.

Authors:  P Flachenecker; B M Taleghani; R Gold; R Grossmann; D Wiebecke; K V Toyka
Journal:  Transfus Sci       Date:  1998-03

Review 8.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Authors:  H Lassmann; W Brück; C Lucchinetti
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

9.  Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Authors:  U A Besinger; K V Toyka; M Hömberg; K Heininger; R Hohlfeld; A Fateh-Moghadam
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

Review 10.  B cell immunobiology in disease: evolving concepts from the clinic.

Authors:  Flavius Martin; Andrew C Chan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527
  10 in total
  11 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

3.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

4.  Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology.

Authors:  Michael R Haupts; Sebastian K Schimrigk; Nils Brune; Andrew Chan; Guido Ahle; Kerstin Hellwig; Fatima B König; Uwe Schlegel; Wolfgang Brück; Ralf Gold
Journal:  J Neurol       Date:  2008-07-14       Impact factor: 4.849

5.  Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.

Authors:  Ying Du; Chuan Li; Yun-Feng Hao; Chao Zhao; Qi Yan; Dan Yao; Lin Li; Wei Zhang
Journal:  J Neurol       Date:  2022-03-03       Impact factor: 6.682

Review 6.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

Review 7.  Current and future standards in treatment of myasthenia gravis.

Authors:  Ralf Gold; Christiane Schneider-Gold
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease.

Authors:  Julius A Steinbeck; Manoj K Jaiswal; Elizabeth L Calder; Sarah Kishinevsky; Andreas Weishaupt; Klaus V Toyka; Peter A Goldstein; Lorenz Studer
Journal:  Cell Stem Cell       Date:  2015-11-05       Impact factor: 24.633

Review 9.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.

Authors:  Raffaele Iorio; Valentina Damato; Paolo Emilio Alboini; Amelia Evoli
Journal:  J Neurol       Date:  2014-10-12       Impact factor: 4.849

Review 10.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.